21.09 - 23.09.2020  STATUS
Virtual - on line

The field of cancer immunology is moving at a rapid pace, with discoveries based on T cell biology and T cell targeted therapeutics eliciting real clinical successes and excitement about the future of cancer care. However, as only twenty percent of patients respond to T cell targeted therapeutics, further work must be done to harness the power of immunology in cancer care. Recent research has shown that myeloid cells create major roadblocks to cancer eradication by promoting immune suppression, angiogenesis and resistance to immune therapy. Advances in the science of these diverse cell types, roles and mechanisms governing myeloid cells in cancer, along with the recent developments of myeloid cell targeted therapeutics, has generated significant interest in the academic and pharmaceutical communities. Conferences that gather experts to focus discussion exclusively on roles of myeloid cells and innate immunity in cancer will help to move our understanding of cancer immune suppression and the field of cancer immune therapy forward. This virtual conference will present the latest developments in our understanding of the origins and contributions of various myeloid cell subsets to tumor growth and metastasis. Additionally, this meeting will challenge paradigms about macrophage and granulocyte origins in tumors, about links between metabolism and function, and about mechanisms by which myeloid cells control immunity. The program will also feature the latest clinical studies of myeloid cell targeted therapeutics in cancer which will stimulate new ideas, collaborations and advance development of new cancer immune therapeutics.

Read more

Protector Members